Your activity: 52 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Chromium injection: Drug information

Chromium injection: Drug information
For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • Micro-Cr
Pharmacologic Category
  • Trace Element, Parenteral
Dosing: Adult
Chromium, parenteral nutrition supplement

Chromium, parenteral nutrition supplement: Note: Chromium contamination is common with other parenteral nutrition products (eg, sodium phosphate, potassium phosphate and magnesium phosphate), which decrease or eliminate the need for routine supplementation (Olson 2019).

Routine supplement: IV: No addition of chromium (or a maximum of 1 mcg/day), due to potential accumulation (Vanek 2012).

Deficiency, prevention: Note: For patients with high intestinal fluid loss who are receiving long-term parenteral nutrition (Jeejeebhoy 1977).

IV: 20 mcg/day added to parenteral nutrition (Jeejeebhoy 1977).

Deficiency, treatment: IV: 150 to 200 mcg/day for up to 2 weeks added to parenteral nutrition, then resume maintenance dose of 20 mcg/day added to parenteral nutrition (Brown 1986; Freund 1979).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution; omit dose in patients with severe kidney disease (Gallieni 1996).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric
Chromium supplement for TPN

Chromium supplement for TPN: Infants, Children, and Adolescents: IV:

Infants 3 to 10 kg: 0.2 mcg/kg/day (Mirtallo 2004).

Children 10 to 40 kg: 0.14 to 0.2 mcg/kg/day (Mirtallo 2004).

Adolescents >40 kg: 5 to 15 mcg/day (Mirtallo 2004).

Manufacturer’s labeling: Dosing in the prescribing information may not reflect current clinical practice. 0.14 to 0.2 mcg/kg/day.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution; consider reducing or omitting dose in patients with severe kidney disease. ASPEN Guidelines recommend decreasing dose in pediatric patients. (Mirtallo 2004)

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing; use with caution.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 40 mcg/10 mL (10 mL)

Generic Equivalent Available: US

Yes

Dosage Forms Considerations

Strength of chromic chloride injection is expressed as elemental chromium

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Micro-Cr: 40 mcg/10 mL (10 mL)

Administration: Adult

IV: For IV use only. Must be diluted prior to use in a volume of fluid not less than 100 mL. Do not administer undiluted by direct injection into a peripheral vein. Solution is acidic; direct intramuscular (IM) or intravenous (IV) injection is contraindicated.

Administration: Pediatric

IV: For IV use only. Typically administered as part of parenteral nutrition solution infusion. Do not administer undiluted by direct injection into a peripheral vein. Solution is acidic; direct IM or IV injection is contraindicated.

Use: Labeled Indications

Chromium, parenteral nutrition supplement: Chromium supplement for parenteral nutrition to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Adverse Reactions

There are no adverse reactions listed in the manufacturer's labeling.

Contraindications

Direct IM or IV injection.

Warnings/Precautions

Concerns related to adverse effects:

• Aluminum toxicity: Contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or in patients with renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of greater than 4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses.

Disease-related concerns:

• Renal impairment: Use with caution in patients with renal impairment; omit dose in patients with severe kidney disease (Gallieni 1996).

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Animal reproduction studies have not been conducted.

Breastfeeding Considerations

It is not known if chromic chloride is present in breast milk. The manufacturer recommends that caution be exercised when administering chromic chloride to nursing women.

Mechanism of Action

Helps to maintain normal glucose metabolism and peripheral nerve function and prevents development of impaired glucose tolerance, ataxia, peripheral neuropathy, and a confusional state similar to mild/moderate hepatic encephalopathy.

Pharmacokinetics

Excretion: Urine and bile.

Pricing: US

Solution (Chromic Chloride Intravenous)

40MCG/10ML (per mL): $2.38 - $3.12

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

  1. Brown RO, Forloines-Lynn S, Cross RE, Heizer WD. Chromium deficiency after long-term total parenteral nutrition. Dig Dis Sci. 1986;31(6):661-664. doi:10.1007/BF01318699 [PubMed 3086063]
  2. Chromic Chloride Injection [package insert]. Lake Forest, IL: Hospira; April 2021.
  3. Freund H, Atamian S, Fischer JE. Chromium deficiency during total parenteral nutrition. JAMA. 1979;241(5):496-498. [PubMed 104057]
  4. Gallieni M, Brancaccio D, Cozzolino M, Sabbioni E. Trace elements in renal failure: are they clinically important? Nephrol Dial Transplant. 1996;11(7):1232-1235. doi:10.1093/ndt/11.7.1232 [PubMed 8672011]
  5. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr. 1977;30(4):531-538. doi:10.1093/ajcn/30.4.531 [PubMed 192066]
  6. Mirtallo J, Canada T, Johnson D, et al; Task Force for the Revision of Safe Practices for Parenteral Nutrition. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004;28(6):S39-70. [PubMed 15568296]
  7. Olson LM, Wieruszewski PM, Jannetto PJ, Abbott JC, McMahon MM, Nystrom EM. Quantitative Assessment of Trace-Element Contamination in Parenteral Nutrition Components. JPEN J Parenter Enteral Nutr. 2019;43(8):970-976. doi:10.1002/jpen.1668 [PubMed 31197862]
  8. Vanek VW, Borum P, Buchman A, et al; Novel Nutrient Task Force, Parenteral Multi-Vitamin and Multi–Trace Element Working Group; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27(4):440-491. doi:10.1177/0884533612446706 [PubMed 22730042]
Topic 109148 Version 38.0